نتائج البحث - "Lebbe, Célèste"

1

دورية أكاديمية

Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial

المصدر: Ascierto, Paolo A; Casula, Milena; Bulgarelli, Jenny; Pisano, Marina; Piccinini, Claudia; Piccin, Luisa; Cossu, Antonio; Mandalà, Mario; Ferrucci, Pier Francesco; Guidoboni, Massimo; Rutkowski, Piotr; Ferraresi, Virginia; Arance, Ana; Guida, Michele; Maiello, Evaristo; Gogas, Helen; Richtig, Erika; Fierro, Maria Teresa; Lebbe, Celeste; Helgadottir, Hildur; Queirolo, Paola; Spagnolo, Francesco; Tucci, Marco; Del Vecchio, Michele; Cao, Maria Gonzales; Minisini, Alessandro Marco; De Placido, Sabino; Sanmamed, Miguel F; Mallardo, Domenico; Dummer, Reinhard; et al (2024). Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial. Nature Communications, 15(1):146.

مصطلحات موضوعية: Dermatology Clinic, 610 Medicine & health, General Physics and Astronomy, General Biochemistry, Genetics and Molecular Biology, General Chemistry, Multidisciplinary

وصف الملف: application/pdf

العلاقة: https://www.zora.uzh.ch/id/eprint/257465/1/ZORA_s41467_023_44475_6.pdfTest; info:pmid/38167503; urn:issn:2041-1723

الإتاحة: https://doi.org/10.5167/uzh-257465Test
https://doi.org/10.1038/s41467-023-44475-6Test
https://www.zora.uzh.ch/id/eprint/257465Test/
https://www.zora.uzh.ch/id/eprint/257465/1/ZORA_s41467_023_44475_6.pdfTest

View record in BASE

النص الكامل

2

دورية أكاديمية

PROM2 overexpression induces metastatic potential through epithelial‐to‐mesenchymal transition and ferroptosis resistance in human cancers

المؤلفون: Paris, Justine, Wilhelm, Claire, Lebbé, Celeste, Elmallah, Mohammed, Pamoukdjian, Frédéric, Héraud, Audrey, Gapihan, Guillaume, Walle, Aurore van De, Tran, van Nhan, Hamdan, Diaddin, Allayous, Clara, Battistella, Maxime, van Glabeke, Emmanuel, Lim, Kah Wai, Leboeuf, Christophe, Roger, Sébastien, Falgarone, Géraldine, Phan, Anh Tuan, Bousquet, Guilhem

المساهمون: Université Paris Cité (UPCité), Université Sorbonne Paris Nord

المصدر: ISSN: 2001-1326 ; Clinical and Translational Medicine ; https://hal.science/hal-04519250Test ; Clinical and Translational Medicine, 2024, 14 (3), ⟨10.1002/ctm2.1632⟩.

مصطلحات موضوعية: [SDV.CAN]Life Sciences [q-bio]/Cancer

العلاقة: hal-04519250; https://hal.science/hal-04519250Test; https://hal.science/hal-04519250/documentTest; https://hal.science/hal-04519250/file/CTM2-14-e1632.pdfTest

الإتاحة: https://doi.org/10.1002/ctm2.1632Test
https://hal.science/hal-04519250Test
https://hal.science/hal-04519250/documentTest
https://hal.science/hal-04519250/file/CTM2-14-e1632.pdfTest

View record in BASE

3

دورية أكاديمية

Sezary syndrome revealed by PD‐L1 blockade for tumor stage mycosis fungoides

المؤلفون: Delaleu, Jérémie, Battistella, Maxime, Ram‐Wolff, Caroline, Moins‐Teisserenc, Hélène, Ta, Van‐Anh, Roelens, Marie, Rivet, Jacqueline, Lebbé, Céleste, Mourah, Samia, Louveau, Baptiste, Bouaziz, Jean‐David, Bagot, Martine, de Masson, Adèle

المصدر: JEADV Clinical Practice ; volume 3, issue 2, page 668-671 ; ISSN 2768-6566 2768-6566

الإتاحة: https://doi.org/10.1002/jvc2.352Test

View record in BASE

4

دورية أكاديمية

Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial

المؤلفون: Ascierto, Paolo A., Casula, Milena, Bulgarelli, Jenny, Pisano, Marina, Piccinini, Claudia, Piccin, Luisa, Cossu, Antonio, Mandalà, Mario, Ferrucci, Pier Francesco, Guidoboni, Massimo, Rutkowski, Piotr, Ferraresi, Virginia, Arance, Ana, Guida, Michele, Maiello, Evaristo, Gogas, Helen, Richtig, Erika, Fierro, Maria Teresa, Lebbe, Celeste, Helgadottir, Hildur, Queirolo, Paola, Spagnolo, Francesco, Tucci, Marco, Del Vecchio, Michele, Cao, Maria Gonzales, Minisini, Alessandro Marco, De Placido, Sabino, Sanmamed, Miguel F., Mallardo, Domenico, Paone, Miriam, Vitale, Maria Grazia, Melero, Ignacio, Grimaldi, Antonio M., Giannarelli, Diana, Dummer, Reinhard, Sileni, Vanna Chiarion, Palmieri, Giuseppe

المساهمون: This study was supported by unconditioned grants from Bristol-Myers Squibb (Princeton, NJ) and Array Biopharma Inc./Pfizer (Boulder, CO).

المصدر: Nature Communications ; volume 15, issue 1 ; ISSN 2041-1723

مصطلحات موضوعية: General Physics and Astronomy, General Biochemistry, Genetics and Molecular Biology, General Chemistry, Multidisciplinary

الإتاحة: https://doi.org/10.1038/s41467-023-44475-6Test
https://www.nature.com/articles/s41467-023-44475-6.pdfTest
https://www.nature.com/articles/s41467-023-44475-6Test

View record in BASE

5

دورية أكاديمية

Line-field confocal optical coherence tomography (LC-OCT) features of a melanotic macule of the lip

المؤلفون: Baroudjian, Barouyr, Raoux, Clothilde, El Zeinaty, Perla, Gandon, Camille, Lebbé, Celeste

المصدر: EJC Skin Cancer ; volume 2, page 100016 ; ISSN 2772-6118

الإتاحة: https://doi.org/10.1016/j.ejcskn.2023.100016Test
https://api.elsevier.com/content/article/PII:S2772611823000162?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2772611823000162?httpAccept=text/plainTest

View record in BASE

6

دورية أكاديمية

First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401

المساهمون: Dummer, Reinhard, Corrie, Pippa, Gutzmer, Ralf, Meniawy, Tarek M, Del Vecchio, Michele, Lebbé, Céleste, Guida, Michele, Dutriaux, Caroline, Dreno, Brigitte, Meyer, Nicola, Ferrucci, Pier Francesco, Dalle, Stéphane, Khattak, Muhammad Adnan, Grob, Jean-Jacque, Briscoe, Karen, Larkin, Jame, Mansard, Sandrine, Lesimple, Thierry, Guidoboni, Massimo, Sabatini, Silvia, Richtig, Erika, Herbst, Rudolf, Lobo, Maurice, Askelson, Margarita, Ascierto, Paolo A, Maio, Michele

مصطلحات موضوعية: Antineoplastic Combined Chemotherapy Protocol, Brain Neoplasm, Human, Ipilimumab, Melanoma, Cutaneous Malignant, Nivolumab, Skin Neoplasm, Uveal melanoma

وصف الملف: STAMPA

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37307514; info:eu-repo/semantics/altIdentifier/wos/WOS:001047586700008; volume:41; issue:23; firstpage:3917; lastpage:3929; numberofpages:13; journal:JOURNAL OF CLINICAL ONCOLOGY; https://hdl.handle.net/11365/1253665Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85167470954

الإتاحة: https://doi.org/10.1200/JCO.22.02199Test
https://hdl.handle.net/11365/1253665Test

View record in BASE

7

دورية أكاديمية

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023

المساهمون: National and Kapodistrian University of Athens (NKUA), Eberhard Karls Universität Tübingen = University of Tübingen, Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Royal Prince Alfred Hospital Sydney, Australia, The University of Sydney, Melanoma Institute Australia Sydney, NSW, Australia, Mount Vernon Cancer Centre Northwood, UK (MV2C), Mount Vernon Cancer Centre, Odense University Hospital (OUH), Immunology and New Concepts in ImmunoTherapy (INCIT), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), University hospital of Zurich Zurich, University of L'Aquila Italy (UNIVAQ), University of Medicine and Pharmacy “Carol Davila” Bucharest (UMPCD), Barts and the London Medical School, University Medical Center of Schleswig–Holstein = Universitätsklinikum Schleswig-Holstein (UKSH), Christian-Albrechts-Universität zu Kiel = Christian-Albrechts University of Kiel = Université Christian-Albrechts de Kiel (CAU), Medizinische Universität Wien = Medical University of Vienna, Medical Faculty Military Medical Academy Belgrade, Serbia (MFM2A), Frankfurt University Hospital, Maastricht University Medical Centre (MUMC), Maastricht University Maastricht, Aristotle University of Thessaloniki, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), CIBER de Enfermedades Raras (CIBERER), Université libre de Bruxelles (ULB), Hospital Universitario Virgen Macarena Séville, Università degli Studi di Roma "La Sapienza" = Sapienza University Rome (UNIROMA), Fondazione Policlinico Universitario A. Gemelli Rome (FPUAG), Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart Roma (Unicatt), Hôpital Ambroise Paré AP-HP, Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie (BECCOH), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Saclay, Universidade de Coimbra Coimbra, Università degli studi di Trieste = University of Trieste, Univerzita Karlova Praha, Česká republika = Charles University Prague, Czech Republic (UK), University Medical Center Utrecht (UMCU), Technische Universität Munchen - Technical University Munich - Université Technique de Munich (TUM), Ludwig Maximilian University Munich = Ludwig Maximilians Universität München (LMU), Aix Marseille Université (AMU), Assistance Publique - Hôpitaux de Marseille (APHM), University of Manchester Manchester, The Christie NHS Foundation Trust Manchester, Royaume-Uni, EADO, EDF, ESTRO, UEMS, EADV and EORTC.

المصدر: ISSN: 0959-8049 ; European Journal of Cancer ; https://inserm.hal.science/inserm-04209605Test ; European Journal of Cancer, 2023, 193, pp.113252. ⟨10.1016/j.ejca.2023.113252⟩.

مصطلحات موضوعية: Adjuvant, Anti-PD-1 antibody, Cemiplimab, Cutaneous squamous cell carcinoma, Follow-up, Locally advanced, Metastatic, Radiotherapy, Surgical excision, Treatment, [SDV]Life Sciences [q-bio]

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37708630; inserm-04209605; https://inserm.hal.science/inserm-04209605Test; https://inserm.hal.science/inserm-04209605/documentTest; https://inserm.hal.science/inserm-04209605/file/PIIS0959804923003544.pdfTest; PUBMED: 37708630

الإتاحة: https://doi.org/10.1016/j.ejca.2023.113252Test
https://inserm.hal.science/inserm-04209605Test
https://inserm.hal.science/inserm-04209605/documentTest
https://inserm.hal.science/inserm-04209605/file/PIIS0959804923003544.pdfTest

View record in BASE

8

دورية أكاديمية

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023

المساهمون: National and Kapodistrian University of Athens (NKUA), Eberhard Karls Universität Tübingen = University of Tübingen, Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), The University of Sydney, Royal Prince Alfred Hospital Sydney, Australia, Melanoma Institute Australia Sydney, NSW, Australia, Mount Vernon Cancer Centre Northwood, UK (MV2C), Mount Vernon Cancer Centre, Odense University Hospital (OUH), Immunology and New Concepts in ImmunoTherapy (INCIT), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), University hospital of Zurich Zurich, University of L'Aquila Italy (UNIVAQ), University of Bucharest (UniBuc), Barts and the London Medical School, Christian-Albrechts-Universität zu Kiel = Christian-Albrechts University of Kiel = Université Christian-Albrechts de Kiel (CAU), Medizinische Universität Wien = Medical University of Vienna, Military Medical Academy Belgrade, Serbia (2MA), Frankfurt University Hospital, Maastricht University Medical Centre (MUMC), Maastricht University Maastricht, Aristotle University of Thessaloniki, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), CIBER de Enfermedades Raras (CIBERER), Hôpital Erasme Bruxelles (ULB), Faculté de Médecine Bruxelles (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB), Hospital Universitario Virgen Macarena Séville, Università degli Studi di Roma "La Sapienza" = Sapienza University Rome (UNIROMA), Fondazione Policlinico Universitario A. Gemelli Rome (FPUAG), Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart Roma (Unicatt), Hôpital Ambroise Paré AP-HP, Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie (BECCOH), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Saclay, Universidade de Coimbra Coimbra, Università degli studi di Trieste = University of Trieste, Univerzita Karlova Praha, Česká republika = Charles University Prague, Czech Republic (UK), University Medical Center Utrecht (UMCU), Aix Marseille Université (AMU), University of Manchester Manchester

المصدر: ISSN: 0959-8049 ; European Journal of Cancer ; https://inserm.hal.science/inserm-04210036Test ; European Journal of Cancer, 2023, 193, pp.113251. ⟨10.1016/j.ejca.2023.113251⟩.

مصطلحات موضوعية: Advanced, Diagnosis, High-risk, Immunosuppression, Invasive cutaneous squamous cell carcinoma, Locally advanced cSCC, Metastatic cSCC, Prevention, Prognosis, Staging, [SDV]Life Sciences [q-bio]